Capstone Holding Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CAPS research report →
Companycapstoneholdingcorp.com
Capstone Therapeutics Corp. , a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism.
- CEO
- Matthew E. Lipman
- IPO
- 1993
- Employees
- 36
- HQ
- Alsip, IL, US
Price Chart
Valuation
- Market Cap
- $2.05M
- P/E
- -0.16
- P/S
- 0.04
- P/B
- 0.32
- EV/EBITDA
- -7.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 24.09%
- Op Margin
- -7.08%
- Net Margin
- -42.86%
- ROE
- -114.76%
- ROIC
- -9.53%
Growth & Income
- Revenue
- $46.88M · 4.47%
- Net Income
- $-21,230,000 · -728.33%
- EPS
- $-4.12 · 88.18%
- Op Income
- $-3,583,000
- FCF YoY
- -222.51%
Performance & Tape
- 52W High
- $2.14
- 52W Low
- $0.26
- 50D MA
- $0.51
- 200D MA
- $0.84
- Beta
- -1.52
- Avg Volume
- 2.06M
Get TickerSpark's AI analysis on CAPS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 30, 26 | SCHULTZ EDWARD CHRISTOPHER | other | 190,000 |
| Mar 30, 26 | Lipman Matthew E. | other | 356,250 |
| Mar 30, 26 | TOPOREK MICHAEL | other | 356,250 |
| Feb 14, 25 | SCHULTZ EDWARD CHRISTOPHER | other | 0 |
| Feb 14, 25 | Lipman Matthew E. | other | 0 |
| Oct 15, 20 | Lipman Matthew E. | other | 6,322 |
| Feb 14, 25 | HOLLIMAN JOHN M III | other | 0 |
| Feb 14, 25 | FELDMAN FREDRIC J | other | 0 |
| Dec 21, 18 | SUBIN NEIL S | sell | 206,000 |
| Dec 21, 18 | SUBIN NEIL S | buy | 103,000 |
Our CAPS Coverage
We haven't published any research on CAPS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CAPS Report →